We are live on ! Find out more
CEROW

CERo Therapeutics Warrants
CEROW

Delisted

CEROW was delisted on the 30th of October, 2025.

Back to rankings

43 hedge funds and large institutions have $2.19M invested in CERo Therapeutics Warrants in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $2.03M → $2.19M (+$155K)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

7% less funds holding

Funds holding: 46 → 43 (-3)

70% less call options, than puts

Call options by funds: $7K | Put options by funds: $23K

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
43
Holders Change
-3
Holders Change %
-6.52%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
5
Closed
4
Calls
$7K
Puts
$23K
Net Calls
-$16K
Net Calls Change
-$20K

Top Buyers

Rank Fund Capital Flow
1
SFM
Spartan Fund Management
Canada
+$3.4K
2
YCM
Yakira Capital Management
Connecticut
+$2.17K
3
RCM
Robinson Capital Management
Michigan
+$159
4
CS
Clear Street
New York
+$88
5
HF
HRT Financial
New York
+$15

Top Sellers

Rank Fund Capital Flow
1
SCM
Shaolin Capital Management
Florida
-$16.3K
2
SRCM
Sage Rock Capital Management
New York
-$3.69K
3
DCM
Difesa Capital Management
New York
-$2.51K
4
SG
StoneX Group
New York
-$911
5
CH
CVI Holdings
Delaware
-$778
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
26
Tenor Capital Management
New York
$3.06K – – –
BI
27
Bulldog Investors
New Jersey
$2.94K -$46 -1,059 -2%
CH
28
CVI Holdings
Delaware
$2.89K -$778 -17,921 -27%
SSA
29
Schonfeld Strategic Advisors
New York
$2.36K – – –
FTUS
30
Flow Traders U.S.
New York
$2K -$113 -2,598 -9%
HF
31
HRT Financial
New York
$2K +$15 +340 +0.9%
CAPTRUST Financial Advisors
32
CAPTRUST Financial Advisors
North Carolina
$1.83K – – –
Walleye Capital
33
Walleye Capital
New York
$1.59K +$4 +100 +0.4%
WA
34
Whitebox Advisors
Minnesota
$1.53K – – –
RCM
35
Rivernorth Capital Management
Florida
$1.5K – – –
SRF
36
Silver Rock Financial
California
$1.41K – – –
GAM
37
Gritstone Asset Management
Maryland
$1.04K – – –
CSS
38
Cubist Systematic Strategies
Connecticut
$1.02K – – –
Walleye Trading
39
Walleye Trading
New York
$824 – – –
Calamos Advisors
40
Calamos Advisors
Illinois
$819 – – –
DCM
41
Dupont Capital Management
Delaware
$819 – – –
RCM
42
Robinson Capital Management
Michigan
$336 +$159 +3,673 +98%
ETH
43
Exos TFP Holdings
New York
$226 – – –
AA
44
Ancora Advisors
Ohio
$163 – – –
SCM
45
Shaolin Capital Management
Florida
– -$16.3K -374,998 Closed
SRCM
46
Sage Rock Capital Management
New York
– -$3.69K -91,999 Closed
DCM
47
Difesa Capital Management
New York
– -$2.51K -62,500 Closed
SG
48
StoneX Group
New York
– -$911 -30,250 Closed
1
2

CEROW Hedge Fund Activity: Q2 2023 in Review

43 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics Warrants (CEROW) for Q2 2023, worth a combined $2.19M — up 7.6% from $2.03M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CEROW and 1 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 5 added.

The largest buyer was Spartan Fund Management, adding an estimated $3.4K. The largest seller was Shaolin Capital Management, exiting entirely with an estimated $16.3K sold.

  • 43 institutional investors held CERo Therapeutics Warrants (CEROW) as of Q2 2023, down from 46 in Q1 2023.
  • Funds reported $2.19M of CERo Therapeutics Warrants stock for Q2 2023, up 7.6% quarter-over-quarter.
  • 1 fund opened new CERo Therapeutics Warrants positions in Q2 2023 and 4 closed out, a net change of -3 holders.
  • The largest CERo Therapeutics Warrants buyer in Q2 2023 was Spartan Fund Management, an estimated $3.4K added.
  • The largest CERo Therapeutics Warrants seller in Q2 2023 was Shaolin Capital Management, an estimated $16.3K sold.

Based on aggregated 13F filings for Q2 2023.